Uppsala, Sweden

Lars Gunne

This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lars Gunne. Retrieved from https://idiyas.com/inventor/lars-gunne

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:

goldMedal1 out of 834,570 
Other
 patents

Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lars Gunne - Innovator in Medicinal Chemistry

Introduction

Lars Gunne is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that affect the dopaminergic system.

Latest Patents

Lars Gunne holds a patent for "2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use." This invention relates to specific chemical compounds that have potential applications in the preparation of medicaments. The compounds are characterized by a general formula that includes various substituents, which can be tailored for specific therapeutic effects.

Career Highlights

Throughout his career, Lars has focused on innovations that enhance the understanding and treatment of conditions related to the central nervous system and circulation. His work has contributed to the advancement of pharmaceutical compositions that can be utilized in clinical settings.

Collaborations

Lars has collaborated with notable colleagues, including Håkan Vilhelm Wikström and Per Erik Andrén. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field of medicinal chemistry.

Conclusion

Lars Gunne's contributions to the field of medicinal chemistry, particularly through his patent on 2-aminothiazol-fused compounds, highlight his role as an innovator. His work continues to influence the development of new therapeutic agents.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…